C030014O09Rik Inhibitors
C030014O09Rik, identified as the RIKEN cDNA C030014O09 gene, is implicated in intricate cellular processes, with potential involvement in gene expression regulation. While the direct inhibitors for C030014O09Rik remain elusive, a theoretical exploration into potential inhibitors targeting crucial signaling pathways provides insights into prospective avenues for future investigations. The interplay of C030014O09Rik with pathways such as PI3K-AKT, MAPK/ERK, TGF-β, and JAK-STAT underscores the complexity of its regulatory mechanisms. Staurosporine, an unspecific kinase inhibitor, exemplifies the range of potential inhibitors that could impact C030014O09Rik by modulating critical signaling pathways. SB203580, as a p38 MAP kinase inhibitor, has the potential to indirectly affect C030014O09Rik by disrupting the p38 MAP kinase activity, a key regulator implicated in gene expression dynamics. Wortmannin and LY294002, both acting as inhibitors of PI3K, may intricately influence cellular responses associated with C030014O09Rik by disrupting the PI3K-AKT pathway. PD98059, a MEK inhibitor, is envisaged to impact C030014O09Rik by altering the MAPK/ERK pathway. SP600125, a JNK inhibitor, could influence the protein by suppressing c-Jun N-terminal kinase activity, altering cellular stress responses linked to C030014O09Rik.
Furthermore, U0126, SB431542, and SB202190, acting on the MAPK and TGF-β pathways, offer potential avenues for indirectly influencing C030014O09Rik by disrupting key signaling cascades. AZD5363, as an AKT kinase inhibitor, is anticipated to modulate cellular processes linked to C030014O09Rik by altering the PI3K-AKT pathway. VX-745, a JAK2 inhibitor, may impact C030014O09Rik by influencing downstream STAT signaling. Rapamycin, as an mTOR inhibitor, has the potential to alter cellular processes associated with C030014O09Rik, affecting the landscape of gene expression. In conclusion, while direct inhibitors for C030014O09Rik are yet to be identified, the exploration of potential inhibitors targeting pivotal signaling pathways provides a foundation for future investigations. The intricate interplay of C030014O09Rik with pathways such as PI3K-AKT, MAPK/ERK, TGF-β, and JAK-STAT necessitates further scrutiny to unravel the specific mechanisms governing its function and potential avenues for modulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, with CAS Number 62996-74-1, is a broad-spectrum kinase inhibitor targeting various protein kinases. Its influence on the cellular environment involves the inhibition of key signaling pathways, potentially impacting C030014O09Rik by disrupting kinases crucial for its regulatory mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, identified by CAS Number 152121-47-6, acts as a p38 MAP kinase inhibitor. Its impact on the MAPK pathway, particularly p38 MAP kinase, may indirectly affect C030014O09Rik by altering the dynamics of cellular responses associated with this enigmatic protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, recognized by CAS Number 19545-26-7, is a potent phosphoinositide 3-kinase (PI3K) inhibitor. Its modulation of the PI3K-AKT pathway is envisaged to influence C030014O09Rik indirectly, perturbing the signaling cascades converging upon its regulatory domains and potentially impacting its functionality. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, with CAS Number 167869-21-8, serves as a MEK inhibitor, disrupting the MAPK/ERK pathway. The hypothetical impact of PD98059 on C030014O09Rik involves the inhibition of MEK1, thereby altering the MAPK signaling cascade and influencing the protein's regulatory mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, functioning as a PI3K inhibitor and identified by CAS Number 154447-36-6, is anticipated to intricately influence cellular responses linked to C030014O09Rik by modulating the PI3K-AKT pathway, potentially altering the dynamics of gene expression and cellular processes associated with this protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, acting as a JNK inhibitor and represented by CAS Number 129-56-6, may indirectly influence C030014O09Rik by suppressing c-Jun N-terminal kinase activity. This suppression could impact gene expression dynamics associated with C030014O09Rik by altering cellular stress responses. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, identified by CAS Number 301836-41-9, is a selective inhibitor of the TGF-β type I receptor ALK5. Its modulation of the TGF-β pathway may indirectly impact C030014O09Rik by altering the signaling cascade related to this pathway, potentially influencing the protein's regulatory mechanisms. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB202190, acting as a p38 MAP kinase inhibitor with CAS Number 152121-30-7, may indirectly influence C030014O09Rik by disrupting p38 MAP kinase activity. The disruption of this kinase, a key regulator in cellular processes, could impact the regulatory mechanisms of C030014O09Rik. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, with CAS Number 1143532-39-1, is an AKT kinase inhibitor. Its modulation of the PI3K-AKT pathway is anticipated to intricately influence cellular processes linked to C030014O09Rik, potentially altering the dynamics of gene expression and regulatory mechanisms associated with this protein. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745, denoted by CAS Number 209410-46-8, is an envisioned JAK2 inhibitor that targets the JAK-STAT pathway. The speculative influence of VX-745 on C030014O09Rik centers around its capacity to impact downstream STAT signaling, potentially altering the cellular responses linked to the protein's regulatory mechanisms. | ||||||